Small companies, small molecules

Survey of small molecule DD companies. Especially interesting is Targen, who's efforts are described here (Src and PI-3).

Also interesting is how one company (Biotica) seems to exist to develop derivatives of rapamycin, seeking greater efficacy and stability.

PI3 summary

Great summary article on the merits of PI3 gamma as a drug target in many indications.

Company with PI-3 compound under development sold

Small deal, with most of the value being NON-PI-3.